ArticleVaccines2023

Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial.

Masoud Solaymani Dodaran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.